Please login to the form below

Not currently logged in
Email:
Password:

Targovax appoints chief financial officer

Dr Erik Digman Wiklund succeeds Oystein Soug

Targovax Dr Erik Digman WiklundTargovax has appointed Dr Erik Digman Wiklund as its new chief financial officer from April this year, succeeding Oystein Soug who became the firm's chief executive officer in November 2016.

Dr Wiklund joins the Oslo, Norway-based immuno-oncology specialist from Aker Biomarine Antarctic, where he served as director of product innovation.

He also brings experience from cancer biotech Algeta ASA, and management consulting expertise from McKinsey & Company's pharma and healthcare practice.

Soug said: “We are delighted to announce the appointment of Erik as our new chief financial officer.

“He has an impressive track record in commercial and operational roles in the biotechnology industry, combined with a strong scientific background.

“Erik's breadth of expertise will be key as we approach a number of important milestones in 2017 and 2018 within our innovative clinical pipeline, designed to help patients' own immune system to fight cancer.”

18th January 2017

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...